Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated

(Thomson Reuters ONE) -
Vifor Pharma Ltd. /
Appointments at the Galenica Group: New management at Vifor Pharma and new
Galenica Group CFO designated
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

The Board of Directors of the Galenica Group has designated Stefan Schulze,
currently CEO of Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as Chief
Operating Officer (COO) and President of the Executive Committee of Vifor
Pharma. Under the proven leadership of the Executive Chairman of the Board of
Directors, Etienne Jornod, Stefan Schulze will take over this position from the
Annual General Meeting of Galenica Ltd. in May 2017.
In so doing, the Board of Directors is entrusting the management of Vifor
Pharma, with its unique business model that combines pharma expertise with
innovative business partnerships and close access to patients, to two very
experienced individuals with complementary skills. Together with the Executive
Committee, they will meet the numerous tasks and challenges facing the company
during a period of rapid growth in order to lead Vifor Pharma successfully to
independence.
Until the 2017 Annual General Meeting, Gianni Zampieri will remain responsible
for the operational management of Vifor Pharma and will gradually introduce
Stefan Schulze to the various duties and responsibilities. In parallel, Stefan
Schulze will look for his successor as CEO of VFMCRP. At the next Annual General
Meeting, Gianni Zampieri will be proposed to shareholders for election to the
Board of Directors.

The Board of Directors has also appointed Felix Burkhard as CFO of the Galenica
Group with effect from 1 January 2017. From that date, Felix Burkhard will take
over as CFO from Jörg Kneubühler, who has held the dual role of CFO of the
Galenica Group and CEO of Galenica Santé since 2014. He will in future

concentrate fully on his role as CEO of Galenica Santé.

VIFOR PHARMA

New corporate management with a proven track record
In May 2016, the Board of Directors of the Galenica Group decided to strengthen
the management of Vifor Pharma by appointing new leadership to maximise the
company's strong growth and profit momentum and further build on it. Since then,
Vice-CEO Gianni Zampieri has successfully led Vifor Pharma on an interim basis
and has significantly contributed to the important milestone of the acquisition
of Relypsa as well as to the development in recent years.
At the express wish of the Galenica Board of Directors, the largest shareholders
and key partners, Etienne Jornod has confirmed that he will remain chairman of
the company for an extended period in order to contribute to realising the
projects he has initiated.

The Board of Directors has now designated Stefan Schulze as COO and President of
the Executive Committee of Vifor Pharma. Under the proven leadership of the
Executive Chairman, Etienne Jornod, Stefan Schulze will take over this position
from the 2017 Annual General Meeting of Galenica Ltd.

Etienne Jornod commented: "We took the time needed to evaluate several
candidates. One alternative would have been to choose an outstanding pharma
specialist, but one who was not familiar with the "close access to patients"
model, or to bring on a manager who knows Vifor Pharma very well and comes
precisely from this area. We opted for these variant because of the excellent
knowledge Stefan Schulze brings to further developing the business model of
Vifor Pharma."

With this decision, the management of the company is entrusted to two
individuals who are highly familiar with the unique business model of Vifor
Pharma - combining expertise in pharma with innovative positioning of products
and services based on its in-depth understanding of patient needs in nephrology
through the partnership with Fresenius Medical Care - and who have contributed
to its development. In addition, Vifor Pharma can count on an Expanded Executive
Committee (EEC) which, following recent reinforcements, is primarily composed of
leaders with extensive pharma experience and who have overseen or contributed to
important product launches in Europe, the USA and other countries.
Furthermore, Christoph Springer will become Head of Global Business Development
of Vifor Pharma in addition to his position as Vice-CEO of VFMCRP.

With this experienced management team, Vifor Pharma is well placed to maximise
its growth and development opportunities and meet the major challenges ahead.
These include integrating the recently acquired US company Relypsa and launching
Veltassa(®), continuing the strong growth of Vifor Pharma in general (sales
+35% in the first half of 2016) and of Ferinject(®)/Injectafer(®) in particular
(sales +46% in the first half of 2016) and preparing for a future as an
independent listed company, which is expected to take place in 2017, assuming
that no major market changes or special risks occur during the period.

Stefan Schulze (51) has been CEO of VFMCRP, the common company of Galenica and
Fresenius Medical Care, since 2014. Prior to that he held various senior
positions as Executive Vice President Sales & Marketing and President & General
Manager of Fresenius HemoCare's Adsorber Technology Business Unit, Germany;
President of Fresenius HemoCare, USA; and Senior Vice President Business
Development at Fresenius Medical Care North America, Germany and USA.
Over recent years as CEO of VFMCRP, Stefan Schulze has demonstrated his talents
as an entrepreneur and leader. He has implemented the strategy of the Board of
Directors in a focused and targeted manner and entered into new licensing and
distribution agreements for promising products including Mircera(®), Retacrit(
TM) and Rayaldee(®), with global partners. With the successful growth of VFMCRP
he has made a major contribution to the strong performance of Vifor Pharma.
In addition to this impressive track record and his many years of experience in
the industry and leadership positions, Stefan Schulze also has an excellent
knowledge of the US market. The strategic alliance signed with Relypsa in 2015,
primarily motivated by the partnership in the dialysis market access, was
concluded by VFMCRP under the leadership of Stefan Schulze. With many years of
experience in the USA, he is therefore ideally suited to supervising the launch
of Veltassa(®) in the USA.
He will remain CEO of VFMCRP until a successor has been appointed.

Etienne Jornod (63) has essentially made Vifor Pharma since its founding into
the company it is today through his vision and strategy. His vision is to
establish Vifor Pharma as a major global player in nephrology, cardiology and
gastroenterology. Today, Vifor Pharma has already become a world leader in iron
deficiency products and is well on the way to become a world leader in
nephrology.

Gianni Zampieri (59) has been with the Galenica Group since 1996 and will remain
responsible for the operational management of Vifor Pharma until the next Annual
General Meeting of Galenica Ltd. in 2017. In parallel he will introduce Stefan
Schulze to the requirements of the role until Stefan Schulze takes over as COO
and President of the Executive Committee following the next Annual General
Meeting. Gianni Zampieri will then be proposed to the shareholders for election
to the Board of Directors. He will thus relinquish his operational
responsibilities and support Stefan Schulze and the company as an advisor.

An experienced management team leading Vifor Pharma into independence
Vifor Pharma has developed from being a contract manufacturer into a global
specialty pharma company that partners with the world's leading pharma and
medtech companies, including Roche, Pfizer, Takeda, Daiichi-Sankyo and Fresenius
Medical Care, and regional market leaders like Abdi Ibrahim in Turkey and
Quimica Suiza in Latin America.
The Vifor Pharma management team comprises long-standing members who have been
responsible for realising the various strategic agreements since the foundation
of the company, as well as members who joined the company more recently with
extensive international experience. This blend of skills and expertise will now
lead Vifor Pharma to independence.

Plans are in place to transition to a more traditional governance model with a
Chairman and a CEO once the new leadership team is established and Vifor Pharma
is positioned as an independent company with its unique business model.


GALENICA GROUP

Division of the Galenica Group
The preparations for the division of the Galenica Group planned for 2017 are on
track. In order to create the best possible financial conditions for the
independence of the two Business units Vifor Pharma and Galenica Santé and to
refund the acquisition of Relypsa, which was completed in early September 2016,
the focus is on an Initial Public Offering (IPO) of Galenica Santé. The Board of
Directors will announce its decisions and the details of the division in due
course.

Guidance for the Galenica Group and Vifor Pharma
When Galenica announced the completion of the Relypsa transaction on 2 September
2016, it was stated that the 2016 guidance would be further updated during
October.

As a result of the accelerated closure of the Relypsa transaction from 1 October
to 1 September 2016 and the resulting inclusion of one additional month of the
ramp-up of Veltassa(®), the combined 2016 EBIT of Vifor Pharma is now expected
to be reduced by approximately CHF 120 million compared to the approximately CHF
80 million previously indicated.
The previous guidance of a 10% increase on a comparable basis in respect of the
2016 EBIT for Vifor Pharma excluding Relypsa is being maintained.

Likewise, the previous guidance in respect of 2016 Galenica Group net profit
increasing by approximately 10% before and after deduction of minority interests
on a comparable basis is confirmed.
Finally, the guidance in respect of 2016 Galenica Group net profit decreasing by
approximately CHF 90 million as a result of the investment required to ramp-up
sales of Veltassa(®) is unchanged, despite the accelerated closing of the
Relypsa transaction, due to the recognition of tax assets.

New CFO Galenica Group from January 2017

Felix Burkhard (50), lic. oec. (University of St. Gallen HSG), Swiss certified
accountant, joined the Galenica Group in 1996 and has held various positions
over the years, initially as Corporate Controller Galenica Ltd. From 2000 he was
charged with implementing the retail strategy, first as Deputy and then from
2010 as Head of the Retail Business sector. In 2015 he was appointed Head
Strategic Projects Galenica Group and since then has had special responsibility
for overall management of the preparations for the division of the Group. Felix
Burkhard will retain this responsibility as CFO Galenica Group and after the
division he will hold the position of CFO Galenica Santé.

Jörg Kneubühler (55) joined Galenica in 2002 and has been CFO of the Galenica
Group since 2012. In 2014 he also assumed the newly created position of CEO
Galenica Santé. To allow him to devote himself fully to managing Galenica Santé
in view of the upcoming independence, he will hand over responsibility as CFO
Galenica Group to Felix Burkhard with effect from 1 January 2017.


For further information, please contact:

Media Relations:
Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media(at)galenica.com

Investor Relations:
Jörg Kneubühler, CFO Galenica Group
Tel. +41 58 852 85 29
 E-mail: investors(at)galenica.com

Galenica is a diversified Group active throughout the healthcare market which,
among other activities, develops, manufactures and markets pharmaceutical
products, runs pharmacies, provides logistical and database services and sets up
networks. With its two Business units Vifor Pharma and Galenica Santé, the
Galenica Group enjoys a leading position in all its core business activities. A
large part of the Group's income is generated by international operations.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN,
security number 1,553,646).

Additional information concerning the Galenica Group can be found at
www.galenica.com.

Press Release (PDF):
http://hugin.info/148637/R/2047184/765192.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vifor Pharma Ltd. via GlobeNewswire

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 06.10.2016 - 07:02 Uhr
Sprache: Deutsch
News-ID 499057
Anzahl Zeichen: 13940

contact information:
Town:

Glattbrugg

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 320 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Appointments at the Galenica Group: New management at Vifor Pharma and new Galenica Group CFO designated"
steht unter der journalistisch-redaktionellen Verantwortung von

Vifor Pharma Ltd. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von Vifor Pharma Ltd.